跳至主要内容
临床试验/NL-OMON40412
NL-OMON40412已完成不适用

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects with Rheumatoid Arthritis - Phase 1 SD, MD in HV and RA patients

Five Prime Therapeutics, Inc.0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • part 1 and 2:
  • - Healthy adult male and female subjects
  • - Ages 21*55 years inclusive
  • - BMI 18-32 kg/m2 inclusive;part 3:
  • n/a for The Netherlands, will be executed in Eastern Europe

排除标准

  • Subjects who have a clinically relevant history or presence of any clinically significant disease or disorder, that in the opinion of the investigator would place the subject at undue risk.

研究者

相似试验

已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study to Assess the Safety and Tolerability of JNJ-67670187 in Healthy ParticipantsUlcerative colitisIBD
NL-OMON47984Janssen-Cilag International NV98
已完成
1 期
A First-in-Human Phase 1 Study to evaluate the Safety and Tolerability of Single ascending doses of GSBR-1290 in Healthy Adult participants.Type 2 Diabetes Mellitus
ACTRN12622000084785Gasherbrum Bio Pty Ltd. (Australian entity of ShouTi Inc)48
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX105 in Normal Healthy VolunteersNeurological- and autoimmune disorders1000381610029305
NL-OMON53467Annexon, Inc.48
终止
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.This current study is being conducted in healthy volunteers to learn about the way this drug behaves in the body when it is given at different doses. The study will also be conducted in patients with Hepatitis C genotype 1.Infection - Other infectious diseases
ACTRN12614000304639Achillion Pharmaceuticals, Inc157
已完成
1 期
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882 in Healthy Adult Male VolunteersHyperuricemia
ACTRN12619000908134Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.30